About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
May 20, 2019 2:06 PM EDT
Can-Fite BioPharma Announces $6 Million Registered Direct Offering
May 20, 2019 7:00 AM EDT
Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)
May 6, 2019 7:00 AM EDT
Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson
May 1, 2019 4:05 PM EDT
Can-Fite Announces ADS Ratio Change
Apr 15, 2019 7:00 AM EDT
Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea
Apr 10, 2019 7:07 AM EDT
Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
Apr 2, 2019 9:00 AM EDT
Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering
Mar 29, 2019 4:30 PM EDT
Can-Fite Files Annual Report for the Year Ended December 31, 2018
Mar 28, 2019 7:00 AM EDT
Can-Fite Reports 2018 Financial Results & Provides Clinical Update
Mar 26, 2019 7:00 AM EDT
Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
<< Previous
1...
4
5
6
7
8
9
10
11
12
13
...30
Next >>
Show All
